Paper35923716
FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms.
Acharya B and 4 others. RSC Med Chem, 2022. Cited by 29 papers, by iCite.
Cite this record
ConductScience Library. FLT3 inhibitors for acute myeloid leukemia: successes, defeats, and emerging paradigms. Papers, record 35923716. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35923716
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| P20 GM109005 | NIGMS NIH HHS | United States | P20GM109005 | PubMed |
Source NIH RePORTER
References122
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 12239147 | Studies of FLT3 mutations in paired presentation and relapse samples from patients with acute myeloid leukemia: implications for the role of FLT3 mutations in leukemogenesis, minimal residual disease detection, and possible therapy with FLT3 inhibitors. | Blood | 2002 | https://conductscience.org/library/papers/12239147 | PubMed |
| 2 | 14985312 | Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. | Invest Ophthalmol Vis Sci | 2004 | https://conductscience.org/library/papers/14985312 | PubMed |
| 3 | 23631653 | FLT3 tyrosine kinase inhibitors in acute myeloid leukemia: clinical implications and limitations. | Leuk Lymphoma | 2014 | https://conductscience.org/library/papers/23631653 | PubMed |
| 4 | 28516360 | Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. | Invest New Drugs | 2017 | https://conductscience.org/library/papers/28516360 | PubMed |
| 5 | 31088841 | Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. | Cancer Discov | 2019 | https://conductscience.org/library/papers/31088841 | PubMed |
| 6 | 30651634 | Targeting FLT3 mutations in AML: review of current knowledge and evidence. | Leukemia | 2019 | https://conductscience.org/library/papers/30651634 | PubMed |
| 7 | 10573574 | Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. | Med Pediatr Oncol | 1999 | https://conductscience.org/library/papers/10573574 | PubMed |
| 8 | 7537980 | FLT3/FLK2 ligand promotes the growth of murine stem cells and the expansion of colony-forming cells and spleen colony-forming units. | Blood | 1995 | https://conductscience.org/library/papers/7537980 | PubMed |
| 9 | 31821677 | FLT3 mutations in acute myeloid leukemia: Therapeutic paradigm beyond inhibitor development. | Cancer Sci | 2020 | https://conductscience.org/library/papers/31821677 | PubMed |
| 10 | 8929245 | Antitumor activity of the new selective protein kinase C inhibitor 4'-N-benzoyl staurosporine on murine and human tumor models. | Arzneimittelforschung | 1995 | https://conductscience.org/library/papers/8929245 | PubMed |
| 11 | 10888033 | PKC412--a protein kinase inhibitor with a broad therapeutic potential. | Anticancer Drug Des | 2000 | https://conductscience.org/library/papers/10888033 | PubMed |
| 12 | 12124172 | CT53518, a novel selective FLT3 antagonist for the treatment of acute myelogenous leukemia (AML). | Cancer Cell | 2002 | https://conductscience.org/library/papers/12124172 | PubMed |
| 13 | 31102119 | Preclinical activity and a pilot phase I study of pacritinib, an oral JAK2/FLT3 inhibitor, and chemotherapy in FLT3-ITD-positive AML. | Invest New Drugs | 2020 | https://conductscience.org/library/papers/31102119 | PubMed |
| 14 | 8822090 | Antitumor effect of CGP41251, a new selective protein kinase C inhibitor, on human non-small cell lung cancer cells. | Jpn J Pharmacol | 1996 | https://conductscience.org/library/papers/8822090 | PubMed |
| 15 | 28645776 | Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study. | Lancet Oncol | 2017 | https://conductscience.org/library/papers/28645776 | PubMed |
| 16 | 24623852 | Crenolanib is a selective type I pan-FLT3 inhibitor. | Proc Natl Acad Sci U S A | 2014 | https://conductscience.org/library/papers/24623852 | PubMed |
| 17 | 12663439 | Sensitivity toward tyrosine kinase inhibitors varies between different activating mutations of the FLT3 receptor. | Blood | 2003 | https://conductscience.org/library/papers/12663439 | PubMed |
| 18 | 17016424 | Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. | Nat Rev Drug Discov | 2006 | https://conductscience.org/library/papers/17016424 | PubMed |
| 19 | 27931243 | Phase 1/2 study of pacritinib, a next generation JAK2/FLT3 inhibitor, in myelofibrosis or other myeloid malignancies. | J Hematol Oncol | 2016 | https://conductscience.org/library/papers/27931243 | PubMed |
| 20 | 3759657 | K-252a, a potent inhibitor of protein kinase C from microbial origin. | J Antibiot (Tokyo) | 1986 | https://conductscience.org/library/papers/3759657 | PubMed |
Cited by19
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 29 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42466468 | FLT3 inhibitors in AML: from classic scaffolds to next-generation approaches. | RSC Adv | 2026 | https://conductscience.org/library/papers/42466468 | PubMed |
| 42220773 | FLT3 Testing and Guideline Concordance in Acute Myeloid Leukemia Across a Community Health System. | Cureus | 2026 | https://conductscience.org/library/papers/42220773 | PubMed |
| 42131843 | CS-DTA: a language model-driven framework for robust drug-target affinity prediction under strict cold-start scenarios. | Front Chem | 2026 | https://conductscience.org/library/papers/42131843 | PubMed |
| 41954160 | Results of a Large-Scale Study of the Binding of 50 Type II Inhibitors to 348 Kinases: The Role of Protein Reorganization. | J Med Chem | 2026 | https://conductscience.org/library/papers/41954160 | PubMed |
| 41757266 | Structural pharmacogenomics of drug-associated SNPs in oral squamous cell carcinoma. | Front Genet | 2026 | https://conductscience.org/library/papers/41757266 | PubMed |
| 41676586 | Results of a large scale study of the binding of 50 type II inhibitors to 348 kinases: The role of protein reorganization. | bioRxiv | 2026 | https://conductscience.org/library/papers/41676586 | PubMed |
| 41557028 | Vascular complications in NPM1-Mutated acute myeloid leukemia: clinical features and prognosis. | Ann Hematol | 2026 | https://conductscience.org/library/papers/41557028 | PubMed |
| 40386346 | Razing the scaffolding: the elimination of non-catalytic functions of kinases through targeted protein degradation. | RSC Med Chem | 2025 | https://conductscience.org/library/papers/40386346 | PubMed |
| 40365393 | IRAK1/4/pan-FLT3 Kinase Inhibitors with Reduced hERG Block as Treatments for Acute Myeloid Leukemia. | ACS Med Chem Lett | 2025 | https://conductscience.org/library/papers/40365393 | PubMed |
| 39813774 | The polypharmacy combination of the BCL-2 inhibitor venetoclax (VEN) and the FLT3 inhibitor gilteritinib (GIL) is more active in acute myeloid leukemia cells than novel polypharmacologic BCL-2/FLT3 VEN-GIL hybrid single-molecule inhibitors. | Eur J Med Chem | 2025 | https://conductscience.org/library/papers/39813774 | PubMed |
| 39569127 | Recent studies on protein kinase signaling inhibitors based on thiazoles: review to date. | RSC Adv | 2024 | https://conductscience.org/library/papers/39569127 | PubMed |
| 39563805 | Discovery of IRAK1/4/pan-FLT3 Kinase Inhibitors as Treatments for Acute Myeloid Leukemia. | ACS Med Chem Lett | 2024 | https://conductscience.org/library/papers/39563805 | PubMed |
| 39263156 | Molecular precision medicine: Multi-omics-based stratification model for acute myeloid leukemia. | Heliyon | 2024 | https://conductscience.org/library/papers/39263156 | PubMed |
| 39091016 | Gilteritinib Reduces FLT3 Expression in Acute Myeloid Leukemia Cells. | Biomol Ther (Seoul) | 2024 | https://conductscience.org/library/papers/39091016 | PubMed |
| 38049337 | [Effect of clonal hematopoiesis in remission on hematopoiesis recovery in patients with NPM1 mutated acute myeloid leukemia after chemotherapy]. | Zhonghua Xue Ye Xue Za Zhi | 2023 | https://conductscience.org/library/papers/38049337 | PubMed |
| 37892567 | A Review of FLT3 Kinase Inhibitors in AML. | J Clin Med | 2023 | https://conductscience.org/library/papers/37892567 | PubMed |
| 37438819 | Indole-based FLT3 inhibitors and related scaffolds as potential therapeutic agents for acute myeloid leukemia. | BMC Chem | 2023 | https://conductscience.org/library/papers/37438819 | PubMed |
| 36622782 | Mechanisms associated with t(7;12) acute myeloid leukaemia: from genetics to potential treatment targets. | Biosci Rep | 2023 | https://conductscience.org/library/papers/36622782 | PubMed |
| 36430695 | Flavones, Flavonols, Lignans, and Caffeic Acid Derivatives from Dracocephalum moldavica and Their In Vitro Effects on Multiple Myeloma and Acute Myeloid Leukemia. | Int J Mol Sci | 2022 | https://conductscience.org/library/papers/36430695 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| FLT3 | 2322 | PubTator's text mining | https://conductscience.org/library/genes/2322 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/35923716
GET https://conductscience.org/api/papers/v1/35923716/references?page=2